The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.
暂无分享,去创建一个
G. Morgan | W. Gregory | M. Drayson | N. Russell | F. Ross | F. Davies | G. Cook | G. Jackson | Julia M. Brown | A. Szubert | J. Child | R. Owen | H. Roddie | C. Rudin | N. N. Coy | S. Bell | Faith E. Davies | Fiona M. Ross | Graham H. Jackson | J. A. Child | Walter M. Gregory | Nigel H. Russell | Gareth J. Morgan | Julia M Brown
[1] S. Lonial. Relapsed multiple myeloma. , 2010, Hematology. American Society of Hematology. Education Program.
[2] A. Hinke,et al. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma , 2010, Haematologica.
[3] R. Hohl,et al. Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. , 2010, Leukemia research.
[4] P. Sonneveld,et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. , 2010, Blood.
[5] B. Barlogie,et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.
[6] B. Pégourié,et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Reynolds,et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Dimopoulos,et al. Treatment of relapsed/refractory multiple myeloma. , 2009, Seminars in hematology.
[9] B. Barlogie,et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. , 2008, Blood.
[10] M. Boccadoro,et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. , 2008, Blood.
[11] D. Reece,et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. , 2008, Cancer treatment reviews.
[12] W. Jędrzejczak,et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] B. Barlogie,et al. Eight‐year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1 , 2008, British journal of haematology.
[14] M. Dimopoulos,et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] L. Mileshkin,et al. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma , 2007, Leukemia & lymphoma.
[16] Serge Leyvraz,et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.
[17] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[18] A. Krishnan,et al. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma , 2006, Bone Marrow Transplantation.
[19] John Crowley,et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. , 2006, The New England journal of medicine.
[20] H. Goldschmidt,et al. A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma , 2006, British journal of haematology.
[21] Rafael Fonseca,et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G Muller,et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.
[23] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[24] R. Souhami,et al. A mathematical model relating response durations to amount of subclinical resistant disease. , 1991, Cancer research.
[25] W. Gregory. Adjusting survival curves for imbalances in prognostic factors. , 1988, British Journal of Cancer.
[26] V. Devita,et al. Conflict of Interest Disclosures , 2018, Global spine journal.